2-47445546-A-G
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.1277-2A>G variant causes a splice acceptor, intron change. The variant allele was found at a frequency of 0.000000692 in 1,445,090 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000251.3 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 6.92e-7 AC: 1AN: 1445090Hom.: 0 Cov.: 27 AF XY: 0.00000139 AC XY: 1AN XY: 720134
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Lynch syndrome 1 Pathogenic:1
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. -
Lynch syndrome Pathogenic:1
Splicing aberration, >2 tumours with MSH2 immunoloss, co-segregation with disease & absent in 1000 genomes -
Lynch-like syndrome Pathogenic:1
- -
Gastric cancer Pathogenic:1
- -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1277-2A>G intronic pathogenic mutation results from an A to G substitution two nucleotides upstream from coding exon 8 in the MSH2 gene. This alteration has been reported in an individual with an MSI-high and MSH2 IHC absent colorectal cancer at age 33 (Overbeek LI et al. Br. J. Cancer, 2007 May;96:1605-12). This alteration has also been reported in two Norwegian families with an aggregation of colorectal cancers and was shown to give rise to aberrant splicing, specifically out of frame exon 8 skipping (Sjursen W et al. J. Med. Genet., 2010 Sep;47:579-85). This alteration has been classified as pathogenic using the following lines of evidence: in silico prediction models, segregation with disease, clinical phenotype including tumor characteristics, mutation co-occurrence, and functional studies (Thompson BA et al. Hum. Mutat. 2013 Jan;34:200-9; Thompson BA et al. Nat. Genet. 2014 Feb;46:107-15; available at [www.insight-group.org/variants/classifications/]). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at